Pollen Allergy Market Predicted to Grow at a CAGR of 2.82% during 2025-2035, Impelled by Rising Prevalence of Pollen Allergies

Pollen Allergy Market Outlook 2025-2035:

The 7 major pollen allergy market are expected to exhibit a CAGR of 2.82% during 2025-2035. The pollen allergy market is expected to witness a sharp growth owing to rising levels of pollution coupled with rising pollen exposure rates, and thus the subsequent rise in the allergic reactions. The growing awareness of allergy treatments and improvements in diagnostic techniques also fuel the market's expansion. Additionally, the demand for products like antihistamines, nasal sprays, and immunotherapy is on the rise. Urbanization and lifestyle changes are contributing to a higher incidence of pollen allergies. Consequently, the market is growing, with key players introducing new products and forming strategic partnerships.

Rising Prevalence of Pollen Allergies: Driving the Pollen Allergy Market

The increasing prevalence of pollen allergies has notably driven the pollen allergy market toward growth. The climate change effects have a noteworthy role in extending pollen seasons, introducing more amounts of pollen into the air. Furthermore, big populations residing in metropolises infuse more pollutants for people who are there to become allergic from pollen as well. In addition, there has been a growing awareness regarding pollen allergies, a development which leads to early diagnosis and treatment for more people. All these advancements in healthcare, from new medicinal drugs for allergies to better diagnostic facilities, are contributing to this growth. In conjunction with the above issues, increase in the elderly population and accessibility to improved healthcare in emerging regions push people to get treatment for their pollen allergy symptom. All these would create a huge market demand needed for treatments, causing the pollen allergy market to grow.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of new treatments for pollen allergies is a major factor fueling market growth. Innovative therapies, such as allergy shots (sublingual and subcutaneous) and biologic drugs, are setting promising possibilities for the intervention for the better management of allergic responses. These biologics, comprising monoclonal antibodies, are specifically designed to interfere with the immune system response to pollen, thus providing a greater relief profile in severe cases than what traditional medications may be able to provide. Some of the other key innovations include oral tablets and nasal sprays that are simply more convenient and easier to use for people. More and more application of personalized medicine, tailored treatment based on knowledge of genetic factors, will ensure even more precise management of allergies. With the rise in awareness of pollen allergies among people, especially in regions where exposure is more, the demand for better treatment options continues to surge. This, in turn, leads to the expansion of the market since people look for methods that are not only effective against their symptoms but also practical to use.

Marketed Therapies in Pollen Allergy Market

Grastek (Grass pollen allergy vaccine table): ALK-Abello

Grastek is an oral immunotherapy sublingual tablet developed by ALK-Abello for the treatment of allergy to grass pollen. It desensitizes the immune system to grass pollen allergens, therefore decreasing allergy symptoms of sneezing, nasal congestion, and itching. Grastek is indicated for patients who suffer from moderate to severe allergic rhinitis due to grass pollen and aims to provide long-term relief from allergic symptoms by gradually exposing the patient to the allergens.

Ragwitek (Ragweed allergy vaccine sublingual tablet): ALK-Abello

Approved by the FDA for sublingual administration of Ragwitek dust-mite immunotherapy tablet developed by ALK-Abello, this treatment is for ragweed pollen allergy. Ragwitek primarily works to desensitize the immune system towards ragweed pollen allergens thereby decreasing symptoms of sneezing, nasal congestion, and itching. Approved for allergic rhinitis with moderate or severe symptoms induced by ragweed, Ragwitek provides long-term relief by the gradual introduction of the allergen into the body.

Oralair (Grass pollen allergy immunotherapy): Stallergenes Greer plc

Oralair is an FDA-approved sublingual immunotherapy tablet developed by Stallergenes Greer for the treatment of grass pollen allergy. It works by desensitizing the immune system to multiple grass pollen allergens, reducing symptoms such as sneezing, nasal congestion, and itching. Approved for patients with moderate to severe grass pollen-induced allergic rhinitis, Oralair provides long-term relief by gradually exposing the body to these allergens. It is most effective when started prior to the grass pollen season.

Emerging Therapies in Pollen Allergy Market

REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is an investigational therapy comprising three fully human monoclonal antibodies designed to treat allergic inflammatory conditions caused by Bet v 1, the primary allergen in birch pollen. Birch pollen allergy is a common cause of seasonal allergies in spring and can also trigger oral allergy syndrome with reactions to related allergens in nuts and fruits like apples, pears, and cherries.

Detailed list of emerging therapies in Pollen Allergy is provided in the final report…

Leading Companies in the Pollen Allergy Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global pollen allergy market, several leading companies are at the forefront of developing integrated platforms to enhance the management of Pollen Allergy. Some of the major players include Astellas Pharma, Regeneron Pharmaceuticals, ALK-Abello, and others. These companies are driving innovation in the pollen allergy market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for Pollen Allergy.

Key Players in Pollen Allergy Market:

The key players in the Pollen Allergy market who are in different phases of developing different therapies are Stallergenes Greer plc, ALK-Abello, Astellas Pharma, Regeneron Pharmaceuticals, and others.

Regional Analysis:

The major markets for Pollen Allergy include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for pollen allergy while also representing the biggest market for its treatment. Recent advancements in immunotherapy treatments, such as sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT), have significantly contributed to the growth of the pollen allergy market by offering long-term relief for patients. Moreover, the integration of digital health tools and personalized medicine is improving the management of pollen allergies, enabling customized treatment plans and real-time monitoring of symptoms. These innovations highlight the continuous progress and expansion in the pollen allergy market.

Key information covered in the report

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pollen allergy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pollen allergy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current pollen allergy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800